NYSE:NVRO - Nevro Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$72.64 -0.43 (-0.59 %)
(As of 05/22/2018 02:09 AM ET)
Previous Close$72.64
Today's Range$72.34 - $74.52
52-Week Range$65.00 - $94.34
Volume348,185 shs
Average Volume425,711 shs
Market Capitalization$2.19 billion
P/E Ratio-58.11
Dividend YieldN/A
Beta-0.52

About Nevro (NYSE:NVRO)

Nevro logoNevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was founded in 2006 and is headquartered in Redwood City, California.

Receive NVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVRO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNYSE:NVRO
CUSIPN/A
Phone650-251-0005

Debt

Debt-to-Equity Ratio0.61
Current Ratio7.99
Quick Ratio6.17

Price-To-Earnings

Trailing P/E Ratio-58.11
Forward P/E Ratio-60.53
P/E GrowthN/A

Sales & Book Value

Annual Sales$326.67 million
Price / Sales6.67
Cash FlowN/A
Price / CashN/A
Book Value$8.41 per share
Price / Book8.64

Profitability

EPS (Most Recent Fiscal Year)($1.25)
Net Income$-36,650,000.00
Net Margins-11.53%
Return on Equity-16.32%
Return on Assets-9.07%

Miscellaneous

Employees676
Outstanding Shares29,980,000

Nevro (NYSE:NVRO) Frequently Asked Questions

What is Nevro's stock symbol?

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

How were Nevro's earnings last quarter?

Nevro (NYSE:NVRO) issued its quarterly earnings results on Thursday, February, 22nd. The medical equipment provider reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.01. The medical equipment provider earned $97.96 million during the quarter, compared to analyst estimates of $96.87 million. Nevro had a negative return on equity of 16.32% and a negative net margin of 11.53%. The firm's revenue for the quarter was up 38.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.34) EPS. View Nevro's Earnings History.

When is Nevro's next earnings date?

Nevro is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Nevro.

What price target have analysts set for NVRO?

9 brokerages have issued 1-year target prices for Nevro's stock. Their forecasts range from $83.00 to $110.00. On average, they anticipate Nevro's stock price to reach $99.1250 in the next twelve months. View Analyst Ratings for Nevro.

Who are some of Nevro's key competitors?

Who are Nevro's key executives?

Nevro's management team includes the folowing people:
  • Mr. Rami Elghandour, Pres, CEO & Director (Age 39)
  • Mr. Andrew H. Galligan, Chief Financial Officer (Age 62)
  • Mr. Patrick Schmitz, VP of Operations (Age 58)
  • Mr. Doug Alleavitch, VP of Quality (Age 57)
  • Mr. Christofer Christoforou, VP of R&D (Age 48)

Has Nevro been receiving favorable news coverage?

News headlines about NVRO stock have been trending somewhat positive this week, according to Accern Sentiment. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Nevro earned a daily sentiment score of 0.00 on Accern's scale. They also assigned news coverage about the medical equipment provider an impact score of 47.19 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Nevro's major shareholders?

Nevro's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.99%), Franklin Resources Inc. (5.23%), Frontier Capital Management Co. LLC (2.79%), Wells Fargo & Company MN (2.76%), Kornitzer Capital Management Inc. KS (2.08%) and Zevenbergen Capital Investments LLC (2.05%). Company insiders that own Nevro stock include Andre Walker, Andrew H Galligan, Doug Alleavitch, Michael Enxing, Michael F Demane, Rami Elghandour and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro.

Which institutional investors are selling Nevro stock?

NVRO stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Allianz Asset Management GmbH, Blair William & Co. IL, Oak Ridge Investments LLC, Frontier Capital Management Co. LLC, Wells Fargo & Company MN, Franklin Resources Inc. and Zevenbergen Capital Investments LLC. Company insiders that have sold Nevro company stock in the last year include Andrew H Galligan, Michael F Demane and Wilfred E Jaeger. View Insider Buying and Selling for Nevro.

Which institutional investors are buying Nevro stock?

NVRO stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Artisan Partners Limited Partnership, Cortina Asset Management LLC, State of Wisconsin Investment Board, Kornitzer Capital Management Inc. KS, BlackRock Inc., Elk Creek Partners LLC and Amundi Pioneer Asset Management Inc.. View Insider Buying and Selling for Nevro.

How do I buy shares of Nevro?

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nevro's stock price today?

One share of NVRO stock can currently be purchased for approximately $72.64.

How big of a company is Nevro?

Nevro has a market capitalization of $2.19 billion and generates $326.67 million in revenue each year. The medical equipment provider earns $-36,650,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis. Nevro employs 676 workers across the globe.

How can I contact Nevro?

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]


MarketBeat Community Rating for Nevro (NVRO)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  292 (Vote Outperform)
Underperform Votes:  157 (Vote Underperform)
Total Votes:  449
MarketBeat's community ratings are surveys of what our community members think about Nevro and other stocks. Vote "Outperform" if you believe NVRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVRO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Nevro (NYSE:NVRO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for Nevro in the last 12 months. Their average twelve-month price target is $99.1250, suggesting that the stock has a possible upside of 36.46%. The high price target for NVRO is $110.00 and the low price target for NVRO is $83.00. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.752.862.86
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $99.1250$97.6250$99.7143$100.5714
Price Target Upside: 36.46% upside12.34% upside46.21% upside13.99% upside

Nevro (NYSE:NVRO) Consensus Price Target History

Price Target History for Nevro (NYSE:NVRO)

Nevro (NYSE:NVRO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/8/2018Canaccord GenuityLower Price TargetBuy ➝ Buy$110.00 ➝ $102.00HighView Rating Details
5/8/2018JMP SecuritiesReiterated RatingMarket Outperform ➝ Overweight$120.00 ➝ $105.00HighView Rating Details
5/8/2018Northland SecuritiesDowngradeOutperform ➝ Market PerformHighView Rating Details
5/8/2018Wells FargoDowngradeOutperform ➝ Market PerformHighView Rating Details
4/4/2018Goldman SachsInitiated CoverageNeutral ➝ Neutral$83.00LowView Rating Details
12/14/2017BMO Capital MarketsReiterated RatingBuy$100.00HighView Rating Details
11/7/2017Leerink SwannReiterated RatingOutperform$105.00 ➝ $110.00N/AView Rating Details
8/8/2017Morgan StanleyBoost Price TargetOverweight$87.00 ➝ $95.00MediumView Rating Details
7/3/2017JPMorgan ChaseReiterated RatingOverweight$102.00LowView Rating Details
5/14/2017B. RileyDowngradeNeutral$85.00LowView Rating Details
8/11/2016Piper Jaffray CompaniesReiterated RatingOverweight$98.00 ➝ $112.00N/AView Rating Details
8/8/2016Bank of AmericaInitiated CoverageBuy$100.00N/AView Rating Details
7/19/2016William BlairInitiated CoverageOutperformN/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Nevro (NYSE:NVRO) Earnings History and Estimates Chart

Earnings by Quarter for Nevro (NYSE:NVRO)

Nevro (NYSE:NVRO) Earnings Estimates

2018 EPS Consensus Estimate: ($0.86)
2019 EPS Consensus Estimate: ($0.43)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.34)($0.13)($0.24)
Q2 20182($0.47)($0.21)($0.34)
Q3 20182($0.41)($0.14)($0.28)
Q4 20181($0.01)($0.01)($0.01)
Q1 20192($0.50)$0.04($0.23)
Q2 20192($0.36)$0.04($0.16)
Q3 20192($0.20)$0.01($0.10)
Q4 20192$0.01$0.10$0.06

Nevro (NYSE NVRO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018        
5/7/2018Q1 2018($0.34)($0.59)$89.32 million$87.64 millionViewN/AView Earnings Details
2/22/2018Q4 2017($0.14)($0.15)$96.87 million$97.96 millionViewListenView Earnings Details
11/6/2017Q3 2017($0.23)($0.21)$80.50 million$82.26 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.29)($0.40)$77.75 million$78.02 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.26)($0.50)$68.71 million$68.40 millionViewListenView Earnings Details
2/23/2017Q416($0.20)($0.34)$66.41 million$70.50 millionViewN/AView Earnings Details
11/7/2016Q316($0.39)($0.14)$58.05 million$60.92 millionViewListenView Earnings Details
8/8/2016Q216($0.47)($0.31)$45.11 million$55.40 millionViewN/AView Earnings Details
5/9/2016Q116($0.65)($0.33)$33.48 million$41.65 millionViewN/AView Earnings Details
2/29/2016Q415($0.56)($0.51)$32.88 million$33.10 millionViewListenView Earnings Details
11/9/2015Q315($0.75)($0.70)$12.51 million$15.40 millionViewN/AView Earnings Details
8/6/2015Q215($0.89)($0.77)$9.65 million$11.40 millionViewN/AView Earnings Details
5/11/2015Q1($0.5430)($0.57)$8.20 million$9.66 millionViewListenView Earnings Details
3/18/2015Q4 2014($0.51)($0.59)$9.72 millionViewN/AView Earnings Details
12/2/2014Q3 2014($0.48)$8.67 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Nevro (NYSE:NVRO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Nevro (NYSE NVRO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.90%
Insider Trading History for Nevro (NYSE:NVRO)
Institutional Ownership by Quarter for Nevro (NYSE:NVRO)

Nevro (NYSE NVRO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/14/2018Andrew H. GalliganCFOSell7,000$76.14$532,980.00View SEC Filing  
3/7/2018Wilfred E JaegerDirectorSell160,542$80.77$12,966,977.341,518View SEC Filing  
3/5/2018Wilfred E JaegerDirectorSell42,116$80.19$3,377,282.041,518View SEC Filing  
3/1/2018Andrew H. GalliganCFOSell7,000$80.10$560,700.00View SEC Filing  
3/1/2018Wilfred E JaegerDirectorSell10,000$80.48$804,800.001,518View SEC Filing  
2/27/2018Wilfred E JaegerDirectorSell14,458$83.28$1,204,062.241,518View SEC Filing  
11/14/2017Andrew H GalliganCFOSell7,000$75.11$525,770.00View SEC Filing  
10/5/2017Michael F DemaneDirectorSell5,000$93.50$467,500.00View SEC Filing  
9/27/2017Michael F. DemaneDirectorSell5,000$91.50$457,500.00View SEC Filing  
9/14/2017Wilfred E JaegerDirectorSell16,467$90.19$1,485,158.731,518View SEC Filing  
9/13/2017Michael F. DemaneDirectorSell5,000$89.50$447,500.00View SEC Filing  
9/11/2017Michael F. DemaneDirectorSell25,000$87.73$2,193,250.00View SEC Filing  
8/24/2017Wilfred E JaegerDirectorSell52,520$86.11$4,522,497.201,518View SEC Filing  
8/21/2017Wilfred E JaegerDirectorSell40,343$84.28$3,400,108.041,518View SEC Filing  
8/16/2017Wilfred E. JaegerDirectorSell79,657$82.74$6,590,820.18View SEC Filing  
8/15/2017Wilfred E. JaegerDirectorSell29,665$82.54$2,448,549.10View SEC Filing  
8/14/2017Andrew H. GalliganCFOSell7,000$82.31$576,170.00View SEC Filing  
8/14/2017Wilfred E. JaegerDirectorSell25,255$82.40$2,081,012.00View SEC Filing  
5/15/2017Andrew H. GalliganCFOSell7,500$75.30$564,750.00View SEC Filing  
5/2/2017Michael F DemaneDirectorSell29,800$96.07$2,862,886.00501,795View SEC Filing  
5/1/2017Rami ElghandourCEOSell10,000$95.03$950,300.00View SEC Filing  
4/4/2017Michael EnxingVPSell1,500$93.53$140,295.00View SEC Filing  
4/4/2017Michael F DemaneDirectorSell22,200$93.39$2,073,258.00517,795View SEC Filing  
4/3/2017Andrew H. GalliganCFOSell30,000$94.46$2,833,800.00View SEC Filing  
3/6/2017Michael EnxingVPSell38,500$91.01$3,503,885.00View SEC Filing  
3/3/2017Wilfred E JaegerDirectorSell43,980$95.03$4,179,419.40View SEC Filing  
1/4/2017Michael EnxingVPSell1,500$75.88$113,820.00View SEC Filing  
12/5/2016Michael EnxingVPSell1,500$76.38$114,570.00View SEC Filing  
11/15/2016Andrew H GalliganCFOSell7,500$86.90$651,750.0033,315View SEC Filing  
10/10/2016Rami ElghandourCEOSell3,000$100.00$300,000.00View SEC Filing  
10/6/2016Michael F DemaneDirectorSell139,514$97.46$13,597,034.44532,425View SEC Filing  
10/4/2016Michael EnxingVPSell1,500$99.31$148,965.0039,463View SEC Filing  
8/22/2016Doug AlleavitchVPSell3,000$100.00$300,000.005,961View SEC Filing  
8/22/2016Wilfred E JaegerDirectorSell154,840$97.79$15,141,803.60View SEC Filing  
8/17/2016Wilfred E JaegerDirectorSell155,160$97.31$15,098,619.60View SEC Filing  
8/15/2016Andrew H GalliganCFOSell7,500$97.71$732,825.0030,079View SEC Filing  
8/10/2016Doug AlleavitchVPSell2,500$95.00$237,500.006,961View SEC Filing  
8/9/2016Michael F DemaneDirectorSell26,667$91.50$2,440,030.50499,252View SEC Filing  
8/4/2016Michael EnxingVPSell1,500$82.06$123,090.0039,463View SEC Filing  
7/29/2016Doug AlleavitchVPSell1,000$85.00$85,000.007,961View SEC Filing  
7/29/2016Michael F DemaneDirectorSell13,333$84.00$1,119,972.00505,919View SEC Filing  
7/11/2016Doug AlleavitchVPSell2,000$80.00$160,000.008,961View SEC Filing  
7/11/2016Michael F DemaneDirectorSell13,333$79.00$1,053,307.00512,586View SEC Filing  
7/5/2016Michael EnxingVPSell1,500$75.39$113,085.0039,463View SEC Filing  
7/1/2016Michael F DemaneDirectorSell13,333$74.00$986,642.00519,253View SEC Filing  
6/8/2016Doug AlleavitchVPSell1,000$75.00$75,000.009,961View SEC Filing  
6/8/2016Rami ElghandourCEOSell7,000$76.59$536,130.0071,180View SEC Filing  
6/6/2016Michael EnxingVPSell1,500$73.29$109,935.0039,463View SEC Filing  
6/2/2016Andre WalkerVPSell4,000$73.50$294,000.004,197View SEC Filing  
6/1/2016Doug AlleavitchVPSell500$72.00$36,000.0010,961View SEC Filing  
5/18/2016Wilfred E JaegerDirectorSell112,983$64.68$7,307,740.44View SEC Filing  
5/16/2016Andrew H GalliganCFOSell10,000$64.78$647,800.0040,000View SEC Filing  
5/16/2016Michael F DemaneCEOSell39,999$64.77$2,590,735.23525,920View SEC Filing  
5/12/2016Rami ElghandourPresidentSell7,000$63.93$447,510.0068,024View SEC Filing  
5/4/2016Michael EnxingVPSell1,500$65.06$97,590.0038,913View SEC Filing  
4/4/2016Michael EnxingVPSell8,767$61.59$539,959.5346,180View SEC Filing  
4/1/2016Rami ElghandourPresidentSell7,000$60.99$426,930.0071,180View SEC Filing  
1/11/2016Andre WalkerVPSell7,987$70.75$565,080.25470View SEC Filing  
1/4/2016Doug AlleavitchVPSell2,514$66.47$167,105.5811,470View SEC Filing  
12/17/2015Andre WalkerVPSell13$69.00$897.00470View SEC Filing  
12/7/2015Rami ElghandourPresidentSell3,500$61.82$216,370.00View SEC Filing  
12/2/2015Andre WalkerVPSell1,000$64.00$64,000.00470View SEC Filing  
12/1/2015Andre WalkerVPSell8,000$59.50$476,000.00470View SEC Filing  
11/30/2015Andre WalkerVPSell6,000$58.50$351,000.00470View SEC Filing  
11/30/2015Rami ElghandourPresidentSell3,500$60.00$210,000.00View SEC Filing  
11/24/2015Andre WalkerVPSell1,000$55.00$55,000.00470View SEC Filing  
11/23/2015Andre WalkerVPSell1,000$54.00$54,000.00470View SEC Filing  
11/23/2015Wilfred E JaegerDirectorSell25,000$53.48$1,337,000.00View SEC Filing  
11/18/2015Wilfred E JaegerDirectorSell175,000$52.24$9,142,000.00View SEC Filing  
11/16/2015Michael F DemaneCEOSell26,667$50.52$1,347,216.84573,941View SEC Filing  
11/13/2015Brad ValeDirectorBuy2,000$50.76$101,520.002,000View SEC Filing  
9/17/2015Andre WalkerVPSell4,000$50.75$203,000.00View SEC Filing  
9/2/2015Michael F DemaneCEOSell40,001$45.11$1,804,445.11600,608View SEC Filing  
6/8/2015& Johnson JohnsonMajor ShareholderSell1,010,265$47.94$48,432,104.10View SEC Filing  
6/8/2015Bay City Capital LlcInsiderSell491,835$47.94$23,578,569.90View SEC Filing  
6/8/2015Wilfred E JaegerDirectorSell393,468$47.94$18,862,855.92View SEC Filing  
11/12/2014& Johnson JohnsonMajor ShareholderBuy40,000$18.00$720,000.00View SEC Filing  
11/12/2014A/S NovoInsiderBuy215,000$18.00$3,870,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Nevro (NYSE NVRO) News Headlines

Source:
DateHeadline
Nevro (NVRO) Downgraded by ValuEngineNevro (NVRO) Downgraded by ValuEngine
www.americanbankingnews.com - May 17 at 5:51 PM
Form 4 NEVRO CORP For: May 14 Filed by: Galligan Andrew HForm 4 NEVRO CORP For: May 14 Filed by: Galligan Andrew H
www.streetinsider.com - May 17 at 5:18 PM
Andrew H. Galligan Sells 7,000 Shares of Nevro (NVRO) StockAndrew H. Galligan Sells 7,000 Shares of Nevro (NVRO) Stock
www.americanbankingnews.com - May 16 at 10:16 PM
Nevro Recognized as a "Best Place to Work" in the Bay AreaNevro Recognized as a "Best Place to Work" in the Bay Area
finance.yahoo.com - May 14 at 4:48 PM
Nevro (NVRO) Expected to Post Quarterly Sales of $96.69 MillionNevro (NVRO) Expected to Post Quarterly Sales of $96.69 Million
www.americanbankingnews.com - May 12 at 3:50 AM
Zacks: Analysts Expect Nevro (NVRO) Will Announce Earnings of -$0.30 Per ShareZacks: Analysts Expect Nevro (NVRO) Will Announce Earnings of -$0.30 Per Share
www.americanbankingnews.com - May 10 at 9:22 AM
Analysts Set Expectations for Nevros Q2 2018 Earnings (NVRO)Analysts Set Expectations for Nevro's Q2 2018 Earnings (NVRO)
www.americanbankingnews.com - May 10 at 6:36 AM
Nevro Expected to Earn Q2 2018 Earnings of ($0.21) Per Share (NVRO)Nevro Expected to Earn Q2 2018 Earnings of ($0.21) Per Share (NVRO)
www.americanbankingnews.com - May 10 at 6:36 AM
Edited Transcript of NVRO earnings conference call or presentation 7-May-18 8:30pm GMTEdited Transcript of NVRO earnings conference call or presentation 7-May-18 8:30pm GMT
finance.yahoo.com - May 9 at 4:50 PM
Nevro (NVRO) Rating Lowered to Sell at Zacks Investment ResearchNevro (NVRO) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - May 9 at 12:09 PM
Q4 2019 Earnings Estimate for Nevro (NVRO) Issued By Leerink SwannQ4 2019 Earnings Estimate for Nevro (NVRO) Issued By Leerink Swann
www.americanbankingnews.com - May 9 at 9:47 AM
William Blair Weighs in on Nevros Q4 2019 Earnings (NVRO)William Blair Weighs in on Nevro's Q4 2019 Earnings (NVRO)
www.americanbankingnews.com - May 9 at 9:47 AM
Wells Fargo Downgrades Nevro Corp (NVRO) to Market PerformWells Fargo Downgrades Nevro Corp (NVRO) to Market Perform
www.streetinsider.com - May 9 at 9:09 AM
Nevro (NVRO) Stock Rating Lowered by ValuEngineNevro (NVRO) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - May 8 at 11:26 PM
Nevro Shares Cross Below 200 DMANevro Shares Cross Below 200 DMA
www.nasdaq.com - May 8 at 4:48 PM
Oversold Conditions For NevroOversold Conditions For Nevro
www.nasdaq.com - May 8 at 4:48 PM
Why Nevro Corp. Is Sinking TodayWhy Nevro Corp. Is Sinking Today
finance.yahoo.com - May 8 at 4:48 PM
Nevro (NVRO) Lowered to "Market Perform" at Northland SecuritiesNevro (NVRO) Lowered to "Market Perform" at Northland Securities
www.americanbankingnews.com - May 8 at 3:45 PM
Nevro (NVRO) Price Target Cut to $105.00Nevro (NVRO) Price Target Cut to $105.00
www.americanbankingnews.com - May 8 at 3:39 PM
Canaccord: Buy The Dip In Nevro After Disappointing Quarterly ReportCanaccord: Buy The Dip In Nevro After Disappointing Quarterly Report
feeds.benzinga.com - May 8 at 3:18 PM
Nevro (NVRO) Downgraded by Wells Fargo to "Market Perform"Nevro (NVRO) Downgraded by Wells Fargo to "Market Perform"
www.americanbankingnews.com - May 8 at 1:41 PM
Nevro (NVRO) Price Target Lowered to $102.00 at Canaccord GenuityNevro (NVRO) Price Target Lowered to $102.00 at Canaccord Genuity
www.americanbankingnews.com - May 8 at 10:22 AM
Nevros (NVRO) CEO Rami Elghandour on Q1 2018 Results - Earnings Call TranscriptNevro's (NVRO) CEO Rami Elghandour on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 9:03 AM
Investors Purchase High Volume of Call Options on Nevro (NVRO)Investors Purchase High Volume of Call Options on Nevro (NVRO)
www.americanbankingnews.com - May 8 at 6:52 AM
Nevro Target of Unusually High Options Trading (NVRO)Nevro Target of Unusually High Options Trading (NVRO)
www.americanbankingnews.com - May 8 at 6:52 AM
Nevro (NVRO) Posts Quarterly  Earnings Results, Misses Expectations By $0.27 EPSNevro (NVRO) Posts Quarterly Earnings Results, Misses Expectations By $0.27 EPS
www.americanbankingnews.com - May 7 at 6:26 PM
Nevro Reports First Quarter 2018 Financial ResultsNevro Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 7 at 4:56 PM
Nevro: 1Q Earnings SnapshotNevro: 1Q Earnings Snapshot
finance.yahoo.com - May 7 at 4:56 PM
Nevro (NVRO) and Orthopediatrics (KIDS) Head to Head ReviewNevro (NVRO) and Orthopediatrics (KIDS) Head to Head Review
www.americanbankingnews.com - May 7 at 3:32 AM
Nevro to Present at the Bank of America Merrill Lynch 2018 Health Care ConferenceNevro to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
finance.yahoo.com - May 2 at 4:51 PM
Nevro (NVRO) Scheduled to Post Earnings on MondayNevro (NVRO) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - April 30 at 2:38 AM
Nevro (NVRO) Receives Consensus Rating of "Hold" from AnalystsNevro (NVRO) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 29 at 5:35 AM
Zacks Investment Research Upgrades Nevro (NVRO) to HoldZacks Investment Research Upgrades Nevro (NVRO) to Hold
www.americanbankingnews.com - April 26 at 6:10 AM
Zacks: Brokerages Anticipate Nevro (NVRO) Will Post Quarterly Sales of $88.45 MillionZacks: Brokerages Anticipate Nevro (NVRO) Will Post Quarterly Sales of $88.45 Million
www.americanbankingnews.com - April 25 at 5:56 AM
Nevro to Report Operating Results for the First Quarter 2018Nevro to Report Operating Results for the First Quarter 2018
finance.yahoo.com - April 23 at 4:42 PM
Zacks: Analysts Anticipate Nevro (NVRO) to Post -$0.34 EPSZacks: Analysts Anticipate Nevro (NVRO) to Post -$0.34 EPS
www.americanbankingnews.com - April 23 at 1:14 AM
Nevro (NVRO) Upgraded by Zacks Investment Research to "Buy"Nevro (NVRO) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 14 at 12:53 PM
Morgan Stanley Boosts Nevro (NVRO) Price Target to $95.00Morgan Stanley Boosts Nevro (NVRO) Price Target to $95.00
www.americanbankingnews.com - April 12 at 5:45 PM
Establishment Labs Appoints Jeremy Livianu as General CounselEstablishment Labs Appoints Jeremy Livianu as General Counsel
globenewswire.com - April 12 at 9:53 AM
Zacks Investment Research Lowers Nevro (NVRO) to HoldZacks Investment Research Lowers Nevro (NVRO) to Hold
www.americanbankingnews.com - April 10 at 7:17 PM
BRIEF-Nevro Corp Says CEO Rami Elghandours FY 2017 Total Compensation Was $13.2 MlnBRIEF-Nevro Corp Says CEO Rami Elghandour's FY 2017 Total Compensation Was $13.2 Mln
www.reuters.com - April 8 at 10:24 AM
$88.57 Million in Sales Expected for Nevro Corp (NVRO) This Quarter$88.57 Million in Sales Expected for Nevro Corp (NVRO) This Quarter
www.americanbankingnews.com - April 8 at 4:48 AM
Investors Buy Large Volume of Call Options on Nevro (NVRO)Investors Buy Large Volume of Call Options on Nevro (NVRO)
www.americanbankingnews.com - April 6 at 7:24 AM
Zacks: Analysts Expect Nevro Corp (NVRO) to Post -$0.34 Earnings Per ShareZacks: Analysts Expect Nevro Corp (NVRO) to Post -$0.34 Earnings Per Share
www.americanbankingnews.com - April 6 at 3:08 AM
Nevro (NVRO) Upgraded at Zacks Investment ResearchNevro (NVRO) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 5 at 11:52 PM
Nevro (NVRO) Earns Hold Rating from Analysts at Goldman SachsNevro (NVRO) Earns Hold Rating from Analysts at Goldman Sachs
www.americanbankingnews.com - April 4 at 8:04 AM
Nevro Corp (NVRO) Given Consensus Rating of "Hold" by BrokeragesNevro Corp (NVRO) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 4 at 5:36 AM
Nevro (NVRO) Raised to Hold at ValuEngineNevro (NVRO) Raised to Hold at ValuEngine
www.americanbankingnews.com - April 3 at 11:04 AM
Nevro (NVRO) Raised to "C-" at TheStreetNevro (NVRO) Raised to "C-" at TheStreet
www.americanbankingnews.com - April 1 at 11:23 AM
These medical devices offer hope for treating chronic pain without opioidsThese medical devices offer hope for treating chronic pain without opioids
www.cnbc.com - March 29 at 4:46 PM

SEC Filings

Nevro (NYSE:NVRO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Nevro (NYSE:NVRO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Nevro (NYSE NVRO) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.